Experimental and computational characterisation of the secondary fragment field in clinical proton therapy beams using microdosimetry
Paper details
Section titled “Paper details”| Field | Value |
|---|---|
| Journal | Precision Radiation Oncology |
| Published | 2026-05-07 |
| Authors | Gabriele Parisi, Marta Missiaggia, Enrico Pierobon, Francesco Cordoni, Enrico Verroi |
| DOI | 10.1002/pro6.70069 |
Secondary fragments made up less than 0.5% of events in a 70.2 MeV clinical proton beam. Their contributions reached up to 2.6% of frequency-mean lineal energy and more than 60% of dose-mean lineal energy. Counting fragments therefore gives a poor indication of their weight in dose-weighted radiation quality.
Rare fragments dominate dose-weighted radiation quality
Section titled “Rare fragments dominate dose-weighted radiation quality”The fragments were heavier ions produced when protons fragmented the target material. The authors report that these ions interact differently with biological tissue than the primary proton beam. They produce denser ionization clusters and much higher LET. The authors suggest that these properties may make fragments important for radiation quality and biological response even when their contribution to physical dose is limited. The reported metrics quantify that distinction.
| Measure | Reported result | Condition |
|---|---|---|
| Secondary fragment share of total events | Less than 0.5% | 70.2 MeV clinical proton beam moderated by 70 mm lung-equivalent material |
| Contribution to frequency-mean lineal energy, (y_F) | Up to 2.6% | 70.2 MeV clinical proton beam moderated by 70 mm lung-equivalent material |
| Contribution to dose-mean lineal energy, (y_D) | More than 60% | 70.2 MeV clinical proton beam moderated by 70 mm lung-equivalent material |
The large difference between (y_F) and (y_D) reflects the heavier fragments’ higher LET and the dose weighting of (y_D). The more than 60% figure applies to dose-mean lineal energy, not to the physical dose delivered by the beam. Thus, a fragment field can be minor by event count and major in the dose-weighted microdosimetric description. The event fraction and the two energy statistics describe different properties of the same field.
Experimental conditions and detector comparison
Section titled “Experimental conditions and detector comparison”The measurements took place at the Trento Proton Therapy Centre. A typical clinical proton beam had an energy of 70.2 MeV. The beam passed through 70 mm of lung-equivalent material before reaching the detectors. The team acquired microdosimetric spectra with two diamond detectors. Their sensitive volumes were 0.85 µm and 12 µm. A spherical tissue-equivalent proportional counter supplied a third detector channel. The acquisition produced separate microdosimetric spectra for each instrument under the stated clinical beam condition. The study compared their responses to determine how sensitive volume and construction alter fragment measurements. This comparison tested whether one measured spectrum could represent the fragment field without instrument-specific corrections. The detector set therefore provides both experimental data and a direct assessment of measurement artefacts.
Classifying fragments with Geant4
Section titled “Classifying fragments with Geant4”The measurements were complemented by Geant4-based Monte Carlo simulations. The custom microdosimetry toolkit focused on secondary-particle characterisation. Events were classified according to their volume of origin and particle type. This step links the measured signals to fragments produced in the target and fragments produced inside detector structures. It also identifies which event classes dominate (y_F) and (y_D). Monte Carlo calculation supplies information that the measured spectrum alone does not expose, particularly for detector self-fragments. The authors describe the custom toolkit as reliable for detector-specific interpretation. Its output remains tied to the instrument that produced the spectrum because geometry and composition alter spectral shape and sensitivity. Without origin information, a measured fragment fraction can be mistaken for a property of the beam rather than the detector response.
Detector geometry changes fragment sensitivity
Section titled “Detector geometry changes fragment sensitivity”Thinner detectors were better suited to detecting fragments generated in the target material. The 0.85 µm diamond detector was therefore the more suitable of the two diamond devices for that task. Detector geometry and composition changed both spectral shape and fragment sensitivity. Solid-state microdosimeters produced self-fragments from their own structure. These events were not representative of the irradiated medium. The TEPC showed the opposite limitation because its walls screened most fragments produced in the target. The two instruments therefore sampled the fragment field with different biases. A higher event count in one detector need not mean that the target field was larger. The recorded spectra reflected both the irradiated medium and the measuring instrument. Any biological model based on those spectra must preserve that distinction.
Context with carbon-ion therapy
Section titled “Context with carbon-ion therapy”Carbon-ion therapy provides the paper’s main reference point because the role of secondary fragments is well recognised there. The role of fragments in proton therapy has remained understudied. The authors attribute this gap to their low frequency and limited impact on physical dose. This study addresses that gap for a typical clinical proton beam rather than the wider hadron-therapy setting. The numerical result is specific to proton therapy. Fragments remained below 0.5% of events but supplied more than 60% of (y_D). The frequency-weighted metric assigned them only up to 2.6%. Both values apply to the 70.2 MeV beam after 70 mm of lung-equivalent moderation. The comparison with carbon-ion therapy is contextual, while the contrast between (y_F) and (y_D) is numerical. The result supports fragment-aware analysis for proton beams specifically.
Limits on biological interpretation
Section titled “Limits on biological interpretation”The study characterizes a microdosimetric field rather than a biological endpoint. The reported work does not test cell survival, tumour response, or patient outcome. The more than 60% (y_D) contribution therefore indicates a potential influence on biological response, not a measured biological effect. Biological models need particle type and volume of origin, not event count alone. Detector artefacts impose a second limitation. Diamond self-fragments can add signal not attributable to the target, while TEPC wall screening can suppress target fragments. Neither effect is removed by treating a measured spectrum as a direct map of the target field. A model calibrated with one detector and applied to another can inherit that bias. Particle-origin information identifies where correction is needed. The reported experiment covers one 70.2 MeV beam and one 70 mm moderator thickness. It does not establish how fragment fractions change with other proton energies or moderation conditions. Results should therefore not be transferred to a different clinical beam without new measurement or validated simulation.
Implications for detector engineering
Section titled “Implications for detector engineering”Detector choice determines which part of the fragment field is measured. A thin solid-state microdosimeter is favourable when target-fragment detection is the goal. Its structure must still be represented when the spectrum is interpreted. A TEPC must include the screening effect of its walls. For diamond instruments, reducing sensitive-volume thickness improves target detection, but self-fragment production still needs accounting. A design intended to reproduce target-fragment spectra must balance thin detection against detector-origin signal. Simulation and measurement should be paired because each has different limitations. The simulation should reproduce the measured geometry and composition. Event classification by volume and particle type should remain part of the analysis. This process separates target fragments from detector-origin events before the spectra enter biological modelling. Spectra used for radiation-quality modelling should report sensitive volume, detector material, and wall construction. Selecting a detector from (y_D) alone would ignore the origin of the events.
Materials and support
Section titled “Materials and support”The paper uses diamond microdosimeters with 0.85 µm and 12 µm sensitive volumes for proton-beam fragment measurements. For enquiries about thin-volume detector material, 6CCVD’s diamond materials catalog lists single-crystal and polycrystalline MPCVD diamond with thickness from 0.1 to 500 µm. The engineering support page provides custom fabrication support for evaluating a detector-specific material and geometry request.
View Original Abstract
Hadron therapy, including protons and carbon-ions, is increasingly used in clinical oncology due to its enhanced biological effectiveness and precision in targeting tumour tissues. While the role of secondary fragments is well recognized in carbon-ion therapy, their contribution in proton therapy remains understudied. This is mainly due to their low frequency of occurrence and limited impact on the physical dose. However, the secondary fragments generated by protons traversing a target material are heavier ions produced by target fragmentation. These interact differently with biological tissue, producing denser ionization clusters and much higher LET. Even though rare, they may substantially affect radiation quality and biological response. This work aims to characterise the secondary fragment field generated by a typical clinical proton beam using microdosimetry, and to evaluate how different detector types influence their measurement and the interpretation of their radiation quality. To this purpose, we performed experiments at the Trento Proton Therapy Centre using a 70.2 MeV proton beam moderated by 70 mm of lung-equivalent material. Microdosimetric spectra were acquired with two diamond detectors (0.85 and 12 µm sensitive volumes) and a spherical tissue-equivalent proportional counter (TEPC). Measurements were complemented by Geant4-based Monte Carlo simulations using a custom microdosimetry toolkit that focuses on the secondaries characterization. Microdosimetric spectra were analysed by classifying events according to their volume of origin and particle type, providing detailed insights into the contribution of secondary fragments. Despite accounting for less than 0.5% of total events, secondary fragments contributed up to 2.6% of the frequency-mean lineal energy ( y ¯ F ${{\bar{y}}_F}$ ) and over 60% of the dose-mean lineal energy ( y ¯ D ${{\bar{y}}_D}$ ), underscoring their relevance. Detector geometry and composition critically influenced spectral shape and sensitivity. Thinner detectors were better suited for target fragment detection. However, while solid-state microdosimeters produced self-fragments from their own structure, which are not representative of the irradiated medium, the TEPC’s walls screened most of the fragments produced in the target material. These intrinsic experimental artefacts highlight the necessity of detector-specific interpretation of spectra when used for biological modelling. The custom Geant4-based microdosimetry toolkit developed proved to be a reliable tool for such interpretation. Overall, our results demonstrate the significant influence of secondary fragments on microdosimetric quantities in proton therapy and stress the importance of fragment-aware, detector-specific approaches for accurate assessment of radiation quality and prediction of biological outcomes.
Products
View Specs →
Single Crystal Cvd Diamond Plate
View Specs →